SI5 Global
Preços
✓ Produto localizado
Medicamentos E Saúde

DIOVAN AMLO FIX VALSARTANA 320MG ANLODIPINO 10MG NOVARTIS CAIXA 28 COMPRIMIDOS REVESTIDOS

N/A
GTIN / EAN
7896261012608
CEST
Não informado
Conteúdo
Não informado

Dados de produto preservados no idioma original.

DIOVAN AMLO FIX VALSARTANA 320MG ANLODIPINO 10MG NOVARTIS CAIXA 28 COMPRIMIDOS REVESTIDOS é fabricado pela N/A, na categoria Medicamentos E Saúde, com código de barras 7896261012608. Classificado no NCM 30049099 (Outros).

Fonte: SI5 Global · código registrado em Brasil · atualizado em 03/10/2026

WhatsApp

Preço base (referência): R$ 189,99 — coletado em paguemenos.com.br em 03/10/2026, pode não estar atualizado

Preço nos últimos 30 dias: R$ 189,99 em 1 loja

Código de barras

7896261012608

Código de barras 7896261012608

Código registrado em Brasil · prefixo 789

Classificação fiscal

NCM
30049099Outros

Descrição do produto

O que é Diovan Amlo Fix 320mg/10mg?

O Diovan Amlo Fix é um medicamento que combina dois princípios ativos, a valsartana e o anlodipino, em um único comprimido. Ele é utilizado para o tratamento da pressão arterial alta, também conhecida como hipertensão. Manter a pressão arterial controlada é fundamental para reduzir os riscos de problemas graves de saúde, como acidente vascular cerebral (AVC), insuficiência cardíaca e insuficiência renal.

Conteúdo da embalagem: 28 comprimidos revestidos de 320mg/10mg.

Fabricado por: Novartis.

Indicação etária: Uso adulto.

Composição Diovan Amlo Fix 320mg/10mg:

Princípio ativo: 320 mg de valsartana e 13,87 mg de besilato de anlodipino (equivalente a 10 mg de anlodipino).

Excipientes: celulose microcristalina, crospovidona, estearato de magnésio, dióxido de silício, amidoglicolato de sódio, hipromelose, dióxido de titânio, óxido de ferro amarelo, macrogol e talco.

Para que serve Diovan Amlo Fix?

O Diovan Amlo Fix serve para tratar a pressão alta. A combinação de seus dois componentes ativos ajuda a relaxar os vasos sanguíneos, facilitando o fluxo de sangue e, consequentemente, diminuindo a pressão arterial. Seus principais objetivos são:

  • Controlar a pressão arterial alta (hipertensão).
  • Reduzir o risco de danos nos vasos sanguíneos do cérebro, coração e rins.
  • Ajudar na prevenção de acidente vascular cerebral (AVC), insuficiência cardíaca e insuficiência renal.

Como devo tomar Diovan Amlo Fix 320mg/10mg?

Siga sempre a orientação do seu médico. A forma de uso recomendada do Diovan Amlo Fix é:

  • Uso oral.
  • A dose recomendada é de um comprimido revestido por dia.
  • Tome o medicamento no mesmo horário todos os dias para manter a eficácia.
  • O comprimido pode ser ingerido com ou sem alimentos.
  • Engula o comprimido inteiro, com um copo de água, sem partir, abrir ou mastigar.
  • Não interrompa o tratamento sem o conhecimento do seu médico.

Quando não devo tomar Diovan Amlo Fix?

Este medicamento não deve ser utilizado nos seguintes casos:

  • Se você tem alergia (hipersensibilidade) ao besilato de anlodipino, à valsartana ou a qualquer outro componente da fórmula.
  • Se você está grávida ou planeja engravidar.
  • Se você tem alto nível de açúcar no sangue e tem diabetes mellitus tipo 2 enquanto está tomando alisquireno.
  • Este medicamento é contraindicado para crianças e adolescentes (menores de 18 anos).
  • Este medicamento é contraindicado durante a amamentação.

Ficha técnica
Medicamento
True
MarcaPropria
Não
NumeroRegistroMS
1.0068.1053.002-8
NomeSubstanciaPrincipioAtivo
Anlodipino, Valsartana
DescricaoBula
%0A%3Ch2%3ELaborat%26%23xF3%3Brio%3C%2Fh2%3E%0A%3Cp%3ENovartis%3C%2Fp%3E%0A%3Ch2%3E%20Apresenta%26%23xE7%3B%26%23xE3%3Bo%20DIOVAN%20%3C%2Fh2%3E%0A%3Cp%3EComprimidos%20revestidos%20sulcados%20de%2040%20mg.%20Embalagens%20com%2014%20e%2028%20comprimidos.%3Cbr%3E%20Comprimidos%20revestidos%20de%2080%20mg%2C%20160%20mg%20e%20320%20mg.%20Embalagens%20com%2014%20e%2028%3Cbr%3E%20comprimidos.%3Cbr%3E%20USO%20ADULTO%3Cbr%3E%3C%2Fp%3E%0A%3Ch2%3E%20DIOVAN%20%26%23x2013%3B%20Indica%26%23xE7%3B%26%23xF5%3Bes%20%3C%2Fh2%3E%0A%3Cp%3E%26%23x95%3B%20Tratamento%20da%20hipertens%26%23xE3%3Bo%20arterial.%20%3Cbr%3E%20%26%23x95%3B%20Tratamento%20de%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%20(classes%20II%20a%20IV%20da%20NYHA)%20em%20pacientes%20recebendo%20tratamento%20padr%26%23xE3%3Bo%20tais%20como%20diur%26%23xE9%3Bticos%2C%20digit%26%23xE1%3Blicos%20e%20tamb%26%23xE9%3Bm%20inibidores%20da%20enzima%20de%20convers%26%23xE3%3Bo%20da%20angiotensina%20ou%20betabloqueadores%2C%20mas%20n%26%23xE3%3Bo%20ambos%3B%20a%20presen%26%23xE7%3Ba%20de%20todas%20estas%20terap%26%23xEA%3Buticas%20padronizadas%20n%26%23xE3%3Bo%20%26%23xE9%3B%20obrigat%26%23xF3%3Bria.%20DIOVAN%20melhora%20a%20morbidade%20nesses%20pacientes%2C%20principalmente%20atrav%26%23xE9%3Bs%20da%20redu%26%23xE7%3B%26%23xE3%3Bo%20da%20hospitaliza%26%23xE7%3B%26%23xE3%3Bo%20por%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca.%20DIOVAN%20retarda%20tamb%26%23xE9%3Bm%20a%20progress%26%23xE3%3Bo%20da%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%2C%20melhora%20a%20classe%20funcional%20da%20NYHA%2C%20a%20fra%26%23xE7%3B%26%23xE3%3Bo%20de%20eje%26%23xE7%3B%26%23xE3%3Bo%2C%20os%20sinais%20e%20sintomas%20da%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%20e%20melhora%20a%20qualidade%20de%20vida%20versus%20o%20placebo%20(vide%20%26%23x93%3BFarmacodin%26%23xE2%3Bmica%26%23x94%3B).%20%3Cbr%3E%20%26%23x95%3B%20DIOVAN%20%26%23xE9%3B%20indicado%20para%20melhorar%20a%20sobrevida%20ap%26%23xF3%3Bs%20infarto%20do%20mioc%26%23xE1%3Brdio%20em%20pacientes%20clinicamente%20est%26%23xE1%3Bveis%20com%20sinais%2C%20sintomas%20ou%20evid%26%23xEA%3Bncia%20radiol%26%23xF3%3Bgica%20de%20insufici%26%23xEA%3Bncia%20ventricular%20esquerda%20e%2Fou%20com%20disfun%26%23xE7%3B%26%23xE3%3Bo%20sist%26%23xF3%3Blica%20ventricular%20esquerda%20(vide%20%26%23x93%3BFarmacodin%26%23xE2%3Bmica%26%23x94%3B).%20%3Cbr%3E%3C%2Fp%3E%0A%3Ch2%3E%20Contra%20indica%26%23xE7%3B%26%23xF5%3Bes%20de%20DIOVAN%20%3C%2Fh2%3E%0A%3Cp%3EHipersensibilidade%20a%20valsartana%20ou%20a%20qualquer%20dos%20excipientes%20da%20formula%26%23xE7%3B%26%23xE3%3Bo%20DIOVAN%20(vide%20%26%23x93%3BComposi%26%23xE7%3B%26%23xE3%3Bo%26%23x94%3B).%20Gravidez%20(vide%20%26%23x93%3BGravidez%20e%20lacta%26%23xE7%3B%26%23xE3%3Bo%26%23x94%3B).%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Ch2%3EAdvert%26%23xEA%3Bncias%3C%2Fh2%3E%0A%3Cp%3EDeple%26%23xE7%3B%26%23xE3%3Bo%20de%20s%26%23xF3%3Bdio%20e%20volume%20%3Cbr%3E%20Em%20pacientes%20com%20deple%26%23xE7%3B%26%23xE3%3Bo%20grave%20de%20s%26%23xF3%3Bdio%20e%2Fou%20hipovolemia%2C%20como%20nos%20que%20estejam%20recebendo%20altas%20doses%20de%20diur%26%23xE9%3Bticos%2C%20pode%20ocorrer%2C%20em%20casos%20raros%2C%20hipotens%26%23xE3%3Bo%20sintom%26%23xE1%3Btica%20ap%26%23xF3%3Bs%20o%20in%26%23xED%3Bcio%20da%20terap%26%23xEA%3Butica%20com%20DIOVAN.%20A%20deple%26%23xE7%3B%26%23xE3%3Bo%20de%20s%26%23xF3%3Bdio%20e%2Fou%20a%20hipovolemia%20devem%20ser%20corrigidas%20antes%20do%20in%26%23xED%3Bcio%20do%20tratamento%20com%20DIOVAN%2C%20por%20exemplo%2C%20pela%20redu%26%23xE7%3B%26%23xE3%3Bo%20da%20dose%20do%20diur%26%23xE9%3Btico.%20Se%20ocorrer%20hipotens%26%23xE3%3Bo%2C%20manter%20o%20paciente%20em%20posi%26%23xE7%3B%26%23xE3%3Bo%20supina%20e%2C%20se%20necess%26%23xE1%3Brio%2C%20administrar%20infus%26%23xE3%3Bo%20venosa%20de%20solu%26%23xE7%3B%26%23xE3%3Bo%20salina%20fisiol%26%23xF3%3Bgica.%20O%20tratamento%20com%20DIOVAN%20pode%20ser%20continuado%2C%20uma%20vez%20que%20a%20press%26%23xE3%3Bo%20arterial%20esteja%20estabilizada.%20%3Cbr%3E%20Estenose%20arterial%20renal%20%3Cbr%3E%20A%20administra%26%23xE7%3B%26%23xE3%3Bo%20de%20DIOVAN%20por%20curto%20prazo%20a%20doze%20pacientes%20com%20hipertens%26%23xE3%3Bo%20renovascular%2C%20secund%26%23xE1%3Bria%20a%20estenose%20de%20art%26%23xE9%3Bria%20renal%20unilateral%2C%20n%26%23xE3%3Bo%20induziu%20qualquer%20altera%26%23xE7%3B%26%23xE3%3Bo%20significativa%20na%20hemodin%26%23xE2%3Bmica%20renal%2C%20na%20creatinina%20s%26%23xE9%3Brica%20ou%20na%20ur%26%23xE9%3Bia%20nitrogenada%20sang%26%23xFC%3B%26%23xED%3Bnea%20(UNS).%20No%20entanto%2C%20como%20os%20medicamentos%20que%20afetam%20o%20sistema%20renina-angiotensina-aldosterona%20(SRAA)%20podem%20aumentar%20a%20ur%26%23xE9%3Bia%20sang%26%23xFC%3B%26%23xED%3Bnea%20e%20a%20creatinina%20s%26%23xE9%3Brica%20em%20pacientes%20com%20estenose%20de%20art%26%23xE9%3Bria%20renal%20unilateral%20ou%20bilateral%2C%20recomenda-se%20a%20monitoriza%26%23xE7%3B%26%23xE3%3Bo%20de%20ambos%20par%26%23xE2%3Bmetros%20desses%20pacientes%20como%20medida%20de%20seguran%26%23xE7%3Ba.%20%3Cbr%3E%20Insufici%26%23xEA%3Bncia%20renal%20%3Cbr%3E%20Nenhum%20ajuste%20de%20dose%20%26%23xE9%3B%20necess%26%23xE1%3Brio%20em%20pacientes%20com%20insufici%26%23xEA%3Bncia%20renal.%20No%20entanto%2C%20n%26%23xE3%3Bo%20existem%20dados%20dispon%26%23xED%3Bveis%20em%20casos%20graves%20%5Bclearance%20(depura%26%23xE7%3B%26%23xE3%3Bo)%20de%20creatinina%20%26lt%3B%2010%20mL%2Fmin%5D%2C%20recomenda-se%20cautela.%20%3Cbr%3E%20Insufici%26%23xEA%3Bncia%20hep%26%23xE1%3Btica%20%3Cbr%3E%20N%26%23xE3%3Bo%20%26%23xE9%3B%20necess%26%23xE1%3Brio%20ajuste%20de%20dose%20em%20pacientes%20com%20insufici%26%23xEA%3Bncia%20hep%26%23xE1%3Btica.%20A%20valsartana%20%26%23xE9%3B%20eliminada%20principalmente%20como%20composto%20inalterado%20na%20bile%2C%20e%20pacientes%20com%20dist%26%23xFA%3Brbios%20biliares%20obstrutivos%20mostraram%20clearance%20(depura%26%23xE7%3B%26%23xE3%3Bo)%20mais%20baixo%20de%20valsartana%20(vide%20%26%23x93%3BFarmacocin%26%23xE9%3Btica%26%23x94%3B).%20%3Cbr%3E%20Deve-se%20tomar%20cuidado%20especial%20ao%20se%20administrar%20valsartana%20a%20pacientes%20com%20dist%26%23xFA%3Brbios%20biliares%20obstrutivos.%20%3Cbr%3E%20Insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%2FP%26%23xF3%3Bs-infarto%20do%20mioc%26%23xE1%3Brdio%20%3Cbr%3E%20Pacientes%20com%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%20ou%20em%20tratamento%20do%20p%26%23xF3%3Bs-infarto%20do%20mioc%26%23xE1%3Brdio%20que%20utilizam%20DIOVAN%20normalmente%20apresentam%20alguma%20redu%26%23xE7%3B%26%23xE3%3Bo%20na%20press%26%23xE3%3Bo%20arterial%2C%20mas%20a%20descontinua%26%23xE7%3B%26%23xE3%3Bo%20da%20terap%26%23xEA%3Butica%20devida%20a%20uma%20hipotens%26%23xE3%3Bo%20sintom%26%23xE1%3Btica%20persistente%20n%26%23xE3%3Bo%20%26%23xE9%3B%20usualmente%20necess%26%23xE1%3Bria%20quando%20a%20posologia%20correta%20%26%23xE9%3B%20seguida.%20Cuidados%20devem%20ser%20tomados%20ao%20iniciar%20o%20tratamento%20em%20pacientes%20com%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%20ou%20p%26%23xF3%3Bs-infarto%20do%20mioc%26%23xE1%3Brdio%20(vide%20%26%23x93%3BPosologia%26%23x94%3B).%20%3Cbr%3E%20Como%20conseq%26%23xFC%3B%26%23xEA%3Bncia%20da%20inibi%26%23xE7%3B%26%23xE3%3Bo%20do%20SRAA%2C%20altera%26%23xE7%3B%26%23xF5%3Bes%20na%20fun%26%23xE7%3B%26%23xE3%3Bo%20renal%20podem%20ser%20antecipadas%20em%20indiv%26%23xED%3Bduos%20suscet%26%23xED%3Bveis.%20Nos%20pacientes%20com%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%20grave%2C%20cuja%20fun%26%23xE7%3B%26%23xE3%3Bo%20renal%20pode%20depender%20da%20atividade%20SRAA%2C%20o%20tratamento%20com%20inibidores%20ECA%20ou%20com%20antagonistas%20do%20receptor%20da%20angiotensina%20foi%20associado%20%26%23xE0%3B%20olig%26%23xFA%3Bria%20e%2Fou%20azotemia%20e%20(raramente)%20com%20insufici%26%23xEA%3Bncia%20renal%20aguda%20e%2Fou%20morte.%20A%20avalia%26%23xE7%3B%26%23xE3%3Bo%20dos%20pacientes%20com%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%20ou%20p%26%23xF3%3Bs-infarto%20do%20mioc%26%23xE1%3Brdio%20deve%20sempre%20incluir%20a%20avalia%26%23xE7%3B%26%23xE3%3Bo%20da%20fun%26%23xE7%3B%26%23xE3%3Bo%20renal.%20Em%20pacientes%20com%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%2C%20cuidados%20devem%20ser%20tomados%20com%20a%20tripla%20combina%26%23xE7%3B%26%23xE3%3Bo%20de%20um%20inibidor%20da%20ECA%2C%20de%20um%20betabloqueador%20e%20valsartana.%20Para%20pacientes%20com%20infarto%20do%20mioc%26%23xE1%3Brdio%20recente%2C%20a%20combina%26%23xE7%3B%26%23xE3%3Bo%20de%20captopril%20e%20valsartana%20n%26%23xE3%3Bo%20demonstrou%20nenhum%20benef%26%23xED%3Bcio%20cl%26%23xED%3Bnico%20adicional%2C%20por%26%23xE9%3Bm%20demonstraram%20um%20aumento%20no%20risco%20dos%20efeitos%20adversos%20comparado%20%26%23xE0%3B%20monoterapia.%20Portanto%2C%20esta%20combina%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20%26%23xE9%3B%20recomendada%20para%20pacientes%20com%20infarto%20do%20mioc%26%23xE1%3Brdio%20recente%2C%20ao%20contr%26%23xE1%3Brio%20da%20monoterapia%20com%20DIOVAN%20que%20%26%23xE9%3B%20indicado%20para%20melhorar%20a%20sobrevida%20ap%26%23xF3%3Bs%20infarto%20do%20mioc%26%23xE1%3Brdio%20em%20pacientes%20clinicamente%20est%26%23xE1%3Bveis%20(vide%20%26%23x93%3BIndica%26%23xE7%3B%26%23xF5%3Bes%26%23x94%3B).%20%3Cbr%3E%3C%2Fp%3E%0A%3Ch2%3EIntera%26%23xE7%3B%26%23xF5%3Bes%20medicamentosas%20de%20DIOVAN%3C%2Fh2%3E%0A%3Cp%3EN%26%23xE3%3Bo%20foram%20observadas%20intera%26%23xE7%3B%26%23xF5%3Bes%20de%20signific%26%23xE2%3Bncia%20cl%26%23xED%3Bnica.%20Entre%20os%20f%26%23xE1%3Brmacos%20com%20os%20quais%20se%20realizaram%20estudos%20cl%26%23xED%3Bnicos%20incluem-se%3A%20cimetidina%2C%20varfarina%2C%20furosemida%2C%20digoxina%2C%20atenolol%2C%20indometacina%2C%20hidroclorotiazida%2C%20amlodipina%20e%20glibenclamida.%20Como%20DIOVAN%20n%26%23xE3%3Bo%20sofre%20extensa%20metaboliza%26%23xE7%3B%26%23xE3%3Bo%20hep%26%23xE1%3Btica%2C%20intera%26%23xE7%3B%26%23xF5%3Bes%20do%20tipo%20drogadroga%2C%20clinicamente%20relevantes%20em%20termos%20de%20indu%26%23xE7%3B%26%23xE3%3Bo%20metab%26%23xF3%3Blica%20ou%20inibi%26%23xE7%3B%26%23xE3%3Bo%20do%20sistema%20do%20citocromo%20P450%2C%20n%26%23xE3%3Bo%20s%26%23xE3%3Bo%20esperadas%20com%20a%20valsartana.%20Embora%20valsartana%20possua%20alta%20taxa%20de%20liga%26%23xE7%3B%26%23xE3%3Bo%20%26%23xE0%3Bs%20prote%26%23xED%3Bnas%20plasm%26%23xE1%3Bticas%2C%20estudos%20in%20vitro%20n%26%23xE3%3Bo%20mostraram%20qualquer%20intera%26%23xE7%3B%26%23xE3%3Bo%20nesse%20n%26%23xED%3Bvel%20com%20uma%20s%26%23xE9%3Brie%20de%20mol%26%23xE9%3Bculas%20que%20tamb%26%23xE9%3Bm%20t%26%23xEA%3Bm%20alta%20taxa%20de%20liga%26%23xE7%3B%26%23xE3%3Bo%20%26%23xE0%3Bs%20prote%26%23xED%3Bnas%20plasm%26%23xE1%3Bticas%2C%20como%20diclofenaco%2C%20furosemida%20e%20varfarina.%20O%20uso%20concomitante%20com%20diur%26%23xE9%3Bticos%20poupadores%20de%20pot%26%23xE1%3Bssio%20(por%20exemplo%2C%20espironolactona%2C%20triantereno%2C%20amilorida)%2C%20suplementos%20%26%23xE0%3B%20base%20de%20pot%26%23xE1%3Bssio%20ou%20substitutos%20do%20sal%20que%20contenham%20pot%26%23xE1%3Bssio%20pode%20acarretar%20aumento%20do%20pot%26%23xE1%3Bssio%20s%26%23xE9%3Brico%20e%2C%20em%20pacientes%20com%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%2C%20aumento%20de%20creatinina%20s%26%23xE9%3Brica.%20Se%20o%20uso%20simult%26%23xE2%3Bneo%20desses%20compostos%20for%20considerado%20necess%26%23xE1%3Brio%2C%20recomenda-se%20cuidado.%20O%20uso%20concomitante%20de%20valsartana%20com%3A%20%3Cbr%3E%20%26%23x2013%3B%20l%26%23xED%3Btio%3A%20pode%20levar%20a%20uma%20intoxica%26%23xE7%3B%26%23xE3%3Bo%20por%20l%26%23xED%3Btio.%20%3Cbr%3E%20%26%23x2013%3B%20antiinflamat%26%23xF3%3Brios%20n%26%23xE3%3Bo-esteroidais%20(AINEs)%3A%20pode%20reduzir%20a%20efic%26%23xE1%3Bcia%20anti-hipertensiva%20%3Cbr%3E%20%26%23x2013%3B%20ritonavir%3A%20aumento%20da%20exposi%26%23xE7%3B%26%23xE3%3Bo%20da%20valsartana%20%3Cbr%3E%20%26%23x2013%3B%20agentes%20que%20bloqueiam%20o%20SRAA%3A%20pode%20levar%20a%20hipercalemia%20%3Cbr%3E%3C%2Fp%3E%0A%3Ch2%3ERea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20%2F%20efeitos%20colaterais%20de%20DIOVAN%3C%2Fh2%3E%0A%3Cp%3EEstudos%20placebo-controlados%20que%20envolveram%202316%20pacientes%20com%20hipertens%26%23xE3%3Bo%20tratados%20com%20DIOVAN%2C%20o%20medicamento%20em%20estudo%20mostrou%20uma%20incid%26%23xEA%3Bncia%20total%20de%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20nesses%20pacientes%20compar%26%23xE1%3Bvel%20ao%20placebo.%20Um%20estudo%20de%20extens%26%23xE3%3Bo%20aberto%20de%206%20meses%20envolvendo%20642%20pacientes%20com%20hipertens%26%23xE3%3Bo%20tratados%20com%20valsartana%20320%20mg%20mostrou%20uma%20incid%26%23xEA%3Bncia%20geral%20de%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20compar%26%23xE1%3Bveis%20%26%23xE0%3Bs%20observadas%20nos%20estudo%20placebo-controlados.%20A%20tabela%20seguinte%20de%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20baseia-se%20em%20dez%20estudos%20placebo-controlados%20nos%20quais%20os%20pacientes%20foram%20tratados%20com%20diversas%20doses%20de%20valsartana%20(10%20mg%20a%20320%20mg)%20por%20at%26%23xE9%3B%2012%20semanas.%20Dos%202316%20pacientes%2C%201281%20e%20660%20receberam%2080%20mg%20ou%20160%20mg%2C%20respectivamente.%20N%26%23xE3%3Bo%20parece%20existir%20uma%20rela%26%23xE7%3B%26%23xE3%3Bo%20entre%20incid%26%23xEA%3Bncia%20e%20dose%20ou%20dura%26%23xE7%3B%26%23xE3%3Bo%20do%20tratamento%20para%20qualquer%20das%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%3B%20conseq%26%23xFC%3Bentemente%20as%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20que%20ocorreram%20com%20todas%20as%20doses%20de%20valsartana%20foram%20agrupadas.%20A%20incid%26%23xEA%3Bncia%20das%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20n%26%23xE3%3Bo%20est%26%23xE1%3B%20associada%20ao%20sexo%2C%20idade%20ou%20ra%26%23xE7%3Ba.%20Todas%20as%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20com%20incid%26%23xEA%3Bncia%20maior%20ou%20igual%20a%201%25%2C%20no%20grupo%20tratado%20com%20DIOVAN%20em%20estudos%20cl%26%23xED%3Bnicos%20placebo-controlados%2C%20est%26%23xE3%3Bo%20inclu%26%23xED%3Bdas%20na%20tabela%201%2C%20independentemente%20da%20sua%20associa%26%23xE7%3B%26%23xE3%3Bo%20causal%20com%20a%20droga%20em%20estudo.%20Tamb%26%23xE9%3Bm%20est%26%23xE3%3Bo%20inclu%26%23xED%3Bdas%20as%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20%26%23xE0%3B%20droga%20de%20relatos%20p%26%23xF3%3Bs-comercializa%26%23xE7%3B%26%23xE3%3Bo%20em%20pacientes%20hipertensos.%20As%20freq%26%23xFC%3B%26%23xEA%3Bncias%20s%26%23xE3%3Bo%20definidas%20como%3A%20muito%20comum%20(%26%23x2265%3B%201%2F10)%3B%20comum%20(%26%23x2265%3B%201%2F100%2C%20%26lt%3B%201%2F10)%3B%20incomum%20(%26%23x2265%3B%201%2F1.000%2C%20%26lt%3B%201%2F100)%3B%20raro%20(%26%23x2265%3B%201%2F10.000%2C%20%26lt%3B%201%2F1.000)%3B%20muito%20raro%20(%26lt%3B%201%2F10.000)%20%3Cbr%3E%20Infec%26%23xE7%3B%26%23xF5%3Bes%20e%20Infesta%26%23xE7%3B%26%23xF5%3Bes%3Cbr%3E%20Comum%3A%3Cbr%3E%20Incomum%3A%3Cbr%3E%20Muito%20raro%3A%3Cbr%3E%20Infec%26%23xE7%3B%26%23xF5%3Bes%20virais%3Cbr%3E%20Infec%26%23xE7%3B%26%23xE3%3Bo%20do%20trato%20respirat%26%23xF3%3Brio%20superior%2C%20faringite%2C%20sinusite%3Cbr%3E%20Rinite%3Cbr%3E%20Dist%26%23xFA%3Brbios%20dos%20sistemas%20linf%26%23xE1%3Btico%20e%20sangu%26%23xED%3Bneo%3Cbr%3E%20Comum%3A%3Cbr%3E%20Muito%20raro%3A%3Cbr%3E%20Neutropenia%3Cbr%3E%20Trombocitopenia%3Cbr%3E%20Dist%26%23xFA%3Brbios%20do%20sistema%20imunol%26%23xF3%3Bgico%3Cbr%3E%20Muito%20raro%3A%20Hipersensibilidade%20incluindo%20doen%26%23xE7%3Ba%20s%26%23xE9%3Brica%3Cbr%3E%20Dist%26%23xFA%3Brbios%20nutricionais%20e%20metab%26%23xF3%3Blicos%3Cbr%3E%20Incomum%3A%20Hipercalemia%23%3Cbr%3E%20Dist%26%23xFA%3Brbios%20psiqui%26%23xE1%3Btricos%3Cbr%3E%20Incomum%3A%20Ins%26%23xF4%3Bnia%2C%20diminui%26%23xE7%3B%26%23xE3%3Bo%20da%20libido%3Cbr%3E%20Dist%26%23xFA%3Brbios%20do%20sistema%20nervoso%3Cbr%3E%20Comum%3A%3Cbr%3E%20Incomum%3A%3Cbr%3E%20Raro%3A%3Cbr%3E%20Muito%20raro%3A%3Cbr%3E%20Tontura%20postural%3Cbr%3E%20S%26%23xED%3Bncope%3Cbr%3E%20Tontura%23%23%3Cbr%3E%20Dor%20de%20cabe%26%23xE7%3Ba%23%23%3Cbr%3E%20Dist%26%23xFA%3Brbios%20do%20labirinto%20e%20ouvido%3Cbr%3E%20Incomum%3A%20Vertigem%3Cbr%3E%20Dist%26%23xFA%3Brbios%20card%26%23xED%3Bacos%3Cbr%3E%20Incomum%3A%20Insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca*%3Cbr%3E%20Dist%26%23xFA%3Brbios%20vasculares%3Cbr%3E%20Comum%3A%3Cbr%3E%20Incomum%3A%3Cbr%3E%20Muito%20raro%3A%3Cbr%3E%20Hipotens%26%23xE3%3Bo%20ortost%26%23xE1%3Btica%23%3Cbr%3E%20Hipotens%26%23xE3%3Bo*%23%23%3Cbr%3E%20Vasculite%3Cbr%3E%20Dist%26%23xFA%3Brbios%20do%20mediastino%2C%20tor%26%23xE1%3Bcicos%20e%20respirat%26%23xF3%3Brios%3Cbr%3E%20Incomum%3A%20Tosse%3Cbr%3E%20Dist%26%23xFA%3Brbios%20gastrointestinais%3Cbr%3E%20Incomum%3A%3Cbr%3E%20Muito%20raro%3A%3Cbr%3E%20diarr%26%23xE9%3Bia%2C%20dor%20abdominal%3Cbr%3E%20N%26%23xE1%3Busea%23%23%3Cbr%3E%20Dist%26%23xFA%3Brbios%20do%20tecido%20subcut%26%23xE2%3Bneo%20e%20pele%3Cbr%3E%20Muito%20raro%3A%20edema%20angioneur%26%23xF3%3Btico**%2C%20erup%26%23xE7%3B%26%23xE3%3Bo%20cut%26%23xE2%3Bnea%2C%20prurido%3Cbr%3E%20Dist%26%23xFA%3Brbios%20do%20tecido%20conectivo%20e%20m%26%23xFA%3Bsculo-esquel%26%23xE9%3Btico%3Cbr%3E%20Incomum%3A%3Cbr%3E%20Muito%20raro%3A%3Cbr%3E%20Dor%20nas%20costas%3Cbr%3E%20Artralgia%2C%20mialgia%3Cbr%3E%20Dist%26%23xFA%3Brbios%20urin%26%23xE1%3Brios%20e%20renais%3Cbr%3E%20Muito%20raro%3A%20Disfun%26%23xE7%3B%26%23xE3%3Bo%20renal**%23%23%2C%20insufici%26%23xEA%3Bncia%20renal%20aguda**%2C%20insufici%26%23xEA%3Bncia%20renal**%3Cbr%3E%20Dist%26%23xFA%3Brbios%20gerais%20e%20condi%26%23xE7%3B%26%23xF5%3Bes%20do%20local%20de%20administra%26%23xE7%3B%26%23xE3%3Bo%3Cbr%3E%20Incomum%3A%20Fadiga%2C%20astenia%2C%20edema%3Cbr%3E%20*relatado%20na%20indica%26%23xE7%3B%26%23xE3%3Bo%20de%20p%26%23xF3%3Bs-infarto%20do%20mioc%26%23xE1%3Brdio%3B%20%23relatado%20na%20indica%26%23xE7%3B%26%23xE3%3Bo%20de%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%3Cbr%3E%20**relatado%20como%20incomum%20na%20indica%26%23xE7%3B%26%23xE3%3Bo%20de%20p%26%23xF3%3Bs-infarto%20do%20mioc%26%23xE1%3Brdio%3B%20%23%23relatado%20mais%20freq%26%23xFC%3Bentemente%20na%20indica%26%23xE7%3B%26%23xE3%3Bo%20de%3Cbr%3E%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%20(comum%3A%20tontura%2C%20disfun%26%23xE7%3B%26%23xE3%3Bo%20renal%2C%20hipotens%26%23xE3%3Bo%3B%20incomum%3A%20dor%20de%20cabe%26%23xE7%3Ba%2C%20n%26%23xE1%3Busea)%3Cbr%3E%20Insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%3Cbr%3E%20As%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20do%20medicamento%20relatadas%20em%20estudos%20duplo-cegos%20de%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%20de%20curta%20dura%26%23xE7%3B%26%23xE3%3Bo%2C%20incluindo%20os%20primeiros%204%20meses%20do%20Estudo%20de%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%20com%20valsartana%20(VAL-HeFT)%2C%20os%20eventos%20adversos%20relacionados%20ao%20medicamento%20foram%20observados%20com%20uma%20incid%26%23xEA%3Bncia%20maior%20que%201%25%20e%20mais%20freq%26%23xFC%3Bentes%20em%20pacientes%20tratados%20com%20valsartana%20do%20que%20com%20placebo%20s%26%23xE3%3Bo%20mostrados%20na%20Tabela%201%20acima.%20Todos%20os%20pacientes%20receberam%20a%20terap%26%23xEA%3Butica%20padr%26%23xE3%3Bo%20para%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%2C%20freq%26%23xFC%3Bentemente%20como%20medica%26%23xE7%3B%26%23xF5%3Bes%20m%26%23xFA%3Bltiplas%2C%20as%20quais%20podiam%20incluir%20diur%26%23xE9%3Bticos%2C%20digit%26%23xE1%3Blicos%2C%20betabloqueadores%20ou%20inibidores%20da%20ECA.%20Dos%20dados%20a%20longo%20prazo%20do%20estudo%20VAL-HeFT%2C%20n%26%23xE3%3Bo%20pareceu%20haver%20nenhum%20evento%20adverso%20significativo%2C%20ainda%20n%26%23xE3%3Bo%20identificado%20durante%20a%20exposi%26%23xE7%3B%26%23xE3%3Bo%20a%20curto%20prazo.%20%3Cbr%3E%20P%26%23xF3%3Bs-infarto%20do%20mioc%26%23xE1%3Brdio%20%3Cbr%3E%20No%20estudo%20duplo-cego%2C%20randomizado%2C%20controlado%20ativamente%20e%20de%20grupos%20paralelos%20VALIANT%2C%20comparando%20a%20efic%26%23xE1%3Bcia%20e%20a%20seguran%26%23xE7%3Ba%20do%20tratamento%20a%20longo%20prazo%20com%20valsartana%2C%20captopril%20e%20suas%20combina%26%23xE7%3B%26%23xF5%3Bes%20em%20pacientes%20de%20alto%20risco%20p%26%23xF3%3Bs-infarto%20do%20mioc%26%23xE1%3Brdio%2C%20o%20perfil%20de%20seguran%26%23xE7%3Ba%20da%20valsartana%20foi%20consistente%20com%20a%20farmacologia%20do%20medicamento%20e%20doen%26%23xE7%3Bas%20de%20base%20com%20fatores%20de%20risco%20cardiovasculares%20e%20com%20o%20curso%20cl%26%23xED%3Bnico%20de%20pacientes%20tratados%20no%20cen%26%23xE1%3Brio%20do%20p%26%23xF3%3Bs-infarto%20do%20mioc%26%23xE1%3Brdio.%20Eventos%20adversos%20s%26%23xE9%3Brios%20(EASs)%20foram%20principalmente%20cardiovasculares%20e%20geralmente%20relacionados%20%26%23xE0%3B%20doen%26%23xE7%3Ba%20de%20base%20como%20refletido%20no%20desfecho%20prim%26%23xE1%3Brio%20de%20efic%26%23xE1%3Bcia%20de%20mortalidade%20por%20todas%20as%20causas.%20Os%20eventos%20adversos%20s%26%23xE9%3Brios%20n%26%23xE3%3Bo%20fatais%20com%20suspeita%20de%20rela%26%23xE7%3B%26%23xE3%3Bo%20com%20o%20medicamento%20estudado%20observados%20com%20uma%20incid%26%23xEA%3Bncia%20de%20%26%23x2265%3B%200%2C1%25%20est%26%23xE3%3Bo%20inclu%26%23xED%3Bdos%20na%20Tabela%201%20acima.%20A%20porcentagem%20de%20descontinua%26%23xE7%3B%26%23xF5%3Bes%20permanentes%20devido%20aos%20eventos%20adversos%20foi%205%2C8%25%20em%20pacientes%20tratados%20com%20valsartana%20e%207%2C7%25%20naqueles%20tratados%20com%20captopril.%20%3Cbr%3E%3C%2Fp%3E%0A%3Ch2%3EDIOVAN%20%26%23x2013%3B%20Posologia%3C%2Fh2%3E%0A%3Cp%3EPosologia%20%3Cbr%3E%20Hipertens%26%23xE3%3Bo%20%3Cbr%3E%20A%20dose%20inicial%20recomendada%20de%20DIOVAN%20%26%23xE9%3B%20de%2080%20mg%20ou%20160%20mg%20uma%20vez%20ao%20dia%2C%20independente%20da%20ra%26%23xE7%3Ba%2C%20idade%20ou%20sexo.%20O%20efeito%20anti-hipertensivo%20manifesta-se%20efetivamente%20dentro%20de%202%20semanas%20e%20o%20efeito%20m%26%23xE1%3Bximo%20ap%26%23xF3%3Bs%204%20semanas.%20Nos%20pacientes%20que%20n%26%23xE3%3Bo%20apresentarem%20controle%20adequado%20da%20press%26%23xE3%3Bo%20arterial%2C%20a%20dose%20di%26%23xE1%3Bria%20pode%20ser%20aumentada%20para%20320%20mg%2C%20ou%20um%20diur%26%23xE9%3Btico%20pode%20ser%20associado.%20DIOVAN%20pode%20ser%20administrado%20concomitantemente%20com%20outros%20agentes%20antihipertensivos.%20%3Cbr%3E%20Insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%20%3Cbr%3E%20A%20dose%20di%26%23xE1%3Bria%20recomendada%20para%20o%20in%26%23xED%3Bcio%20de%20tratamento%20%26%23xE9%3B%20de%2040%20mg%20de%20DIOVAN%20duas%20vezes%20ao%20dia.%20A%20titula%26%23xE7%3B%26%23xE3%3Bo%20para%2080%20mg%20e%20160%20mg%20duas%20vezes%20ao%20dia%20deve%20ser%20feita%20para%20a%20maior%20dose%20conforme%20tolerado%20pelo%20paciente.%20Deve-se%20considerar%20a%20redu%26%23xE7%3B%26%23xE3%3Bo%20da%20dose%20dos%20diur%26%23xE9%3Bticos%20concomitantes.%20A%20dose%20m%26%23xE1%3Bxima%20di%26%23xE1%3Bria%20administrada%20nos%20estudos%20cl%26%23xED%3Bnicos%20%26%23xE9%3B%20de%20320%20mg%20em%20doses%20fracionadas.%20A%20avalia%26%23xE7%3B%26%23xE3%3Bo%20dos%20pacientes%20com%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%20deve%20sempre%20incluir%20a%20avalia%26%23xE7%3B%26%23xE3%3Bo%20da%20fun%26%23xE7%3B%26%23xE3%3Bo%20renal.%20%3Cbr%3E%20P%26%23xF3%3Bs-infarto%20do%20mioc%26%23xE1%3Brdio%20%3Cbr%3E%20A%20terap%26%23xEA%3Butica%20pode%20ser%20iniciada%2012%20horas%20ap%26%23xF3%3Bs%20um%20infarto%20do%20mioc%26%23xE1%3Brdio.%20Ap%26%23xF3%3Bs%20uma%20dose%20inicial%20de%2020%20mg%20duas%20vezes%20ao%20dia%2C%20a%20terap%26%23xEA%3Butica%20com%20valsartana%20deve%20ser%20titulada%20para%2040%20mg%2C%2080%20mg%20e%20160%20mg%20duas%20vezes%20ao%20dia%20durante%20as%20pr%26%23xF3%3Bximas%20semanas.%20A%20dose%20inicial%20%26%23xE9%3B%20oferecida%20por%20comprimidos%20de%2040%20mg%20divis%26%23xED%3Bveis.%20A%20dose-alvo%20m%26%23xE1%3Bxima%20%26%23xE9%3B%20160%20mg%20duas%20vezes%20ao%20dia.%20Em%20geral%2C%20%26%23xE9%3B%20recomendado%20que%20os%20pacientes%20atinjam%20um%20n%26%23xED%3Bvel%20de%20dose%20de%2080%20mg%20duas%20vezes%20ao%20dia%20por%20duas%20semanas%20ap%26%23xF3%3Bs%20o%20in%26%23xED%3Bcio%20do%20tratamento%20e%20que%20o%20atingimento%20da%20dose-alvo%20m%26%23xE1%3Bxima%20ocorra%20em%20tr%26%23xEA%3Bs%20meses%20com%20base%20na%20tolerabilidade%20do%20paciente%20%26%23xE0%3B%20valsartana%20durante%20a%20titula%26%23xE7%3B%26%23xE3%3Bo.%20Se%20hipotens%26%23xE3%3Bo%20sintom%26%23xE1%3Btica%20ou%20disfun%26%23xE7%3B%26%23xE3%3Bo%20renal%20ocorrer%2C%20a%20dose%20deve%20ser%20reduzida.%20A%20valsartana%20pode%20ser%20usada%20em%20pacientes%20tratados%20com%20outras%20terap%26%23xEA%3Buticas%20do%20p%26%23xF3%3Bsinfarto%20do%20mioc%26%23xE1%3Brdio%2C%20por%20exemplo%2C%20trombol%26%23xED%3Bticos%2C%20%26%23xE1%3Bcido%20acetilsalic%26%23xED%3Blico%2C%20betabloqueadores%20ou%20estatinas.%20A%20avalia%26%23xE7%3B%26%23xE3%3Bo%20em%20pacientes%20com%20p%26%23xF3%3Bs-infarto%20do%20mioc%26%23xE1%3Brdio%20deve%20sempre%20incluir%20uma%20avalia%26%23xE7%3B%26%23xE3%3Bo%20da%20fun%26%23xE7%3B%26%23xE3%3Bo%20renal.%20%3Cbr%3E%20Insufici%26%23xEA%3Bncia%20hep%26%23xE1%3Btica%20%3Cbr%3E%20Pacientes%20com%20insufici%26%23xEA%3Bncia%20hep%26%23xE1%3Btica%20de%20leve%20a%20moderada%20somente%20devem%20tomar%20doses%20acima%20de%2080%20mg%20duas%20vezes%20ao%20dia%20se%20o%20benef%26%23xED%3Bcio%20cl%26%23xED%3Bnico%20for%20superior%20ao%20risco%20associado%20com%20a%20exposi%26%23xE7%3B%26%23xE3%3Bo%20aumentada%20a%20valsartana.%20%3Cbr%3E%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Ch2%3ESuper%20dosagem%3C%2Fh2%3E%0A%3Cp%3EA%20superdose%20com%20DIOVAN%20pode%20resultar%20em%20acentuada%20hipotens%26%23xE3%3Bo%20que%20pode%20levar%20a%20uma%20depress%26%23xE3%3Bo%20do%20n%26%23xED%3Bvel%20de%20consci%26%23xEA%3Bncia%2C%20colapso%20circulat%26%23xF3%3Brio%20e%20ou%20choque.%20Se%20a%20ingest%26%23xE3%3Bo%20foi%20recente%2C%20deve-se%20induzir%20o%20v%26%23xF4%3Bmito.%20Caso%20a%20ingest%26%23xE3%3Bo%20tenha%20ocorrido%20h%26%23xE1%3B%20mais%20tempo%2C%20o%20tratamento%20usual%20seria%20a%20infus%26%23xE3%3Bo%20intravenosa%20de%20solu%26%23xE7%3B%26%23xE3%3Bo%20salina%20fisiol%26%23xF3%3Bgica.%20A%20valsartana%20n%26%23xE3%3Bo%20pode%20ser%20removida%20por%20hemodi%26%23xE1%3Blise.%3C%2Fp%3E%0A%3Ch2%3ECaracteristicas%20farmalogicas%3C%2Fh2%3E%0A%3Cp%3EFarmacodin%26%23xE2%3Bmica%3Cbr%3E%20Grupo%20farmacoterap%26%23xEA%3Butico%3A%20bloqueadores%20do%20receptor%20da%20angiotensina%20II%20simples.%20C%26%23xF3%3Bdigo%20ATC%3A%20C09C%20A03.%20O%20horm%26%23xF4%3Bnio%20ativo%20do%20SRAA%20%26%23xE9%3B%20a%20angiotensina%20II%2C%20formada%20a%20partir%20da%20angiotensina%20I%20pela%20ECA.%20A%20angiotensina%20II%20se%20liga%20a%20receptores%20espec%26%23xED%3Bficos%20localizados%20na%20membrana%20das%20c%26%23xE9%3Blulas%20de%20v%26%23xE1%3Brios%20tecidos%2C%20exercendo%20diversos%20efeitos%20fisiol%26%23xF3%3Bgicos%2C%20inclusive%20em%20particular%20no%20envolvimento%20direto%20e%20indireto%20na%20regula%26%23xE7%3B%26%23xE3%3Bo%20da%20press%26%23xE3%3Bo%20arterial.%20Como%20um%20potente%20vasoconstritor%2C%20a%20angiotensina%20II%20exerce%20uma%20resposta%20pressora%20direta.%20Al%26%23xE9%3Bm%20disso%2C%20promove%20reten%26%23xE7%3B%26%23xE3%3Bo%20de%20s%26%23xF3%3Bdio%20e%20estimula%26%23xE7%3B%26%23xE3%3Bo%20da%20secre%26%23xE7%3B%26%23xE3%3Bo%20de%20aldosterona.%20DIOVAN%20(valsartana)%20%26%23xE9%3B%20um%20potente%20e%20espec%26%23xED%3Bfico%20antagonista%20dos%20receptores%20de%20angiotensina%20II%20(Ang%20II)%20ativo%20por%20via%20oral.%20Ele%20atua%20seletivamente%20no%20receptor%20subtipo%20AT1%2C%20respons%26%23xE1%3Bvel%20pelas%20conhecidas%20a%26%23xE7%3B%26%23xF5%3Bes%20da%20angiotensina%20II.%20%3Cbr%3E%20Os%20n%26%23xED%3Bveis%20plasm%26%23xE1%3Bticos%20aumentados%20de%20Ang%20II%20seguindo-se%20ao%20bloqueio%20do%20receptor%20AT1%20com%20valsartana%20pode%20estimular%20o%20receptor%20AT2%20n%26%23xE3%3Bo-bloqueado%2C%20o%20que%20parece%20contrabalan%26%23xE7%3Bar%20o%20efeito%20do%20receptor%20AT1.%20A%20valsartana%20n%26%23xE3%3Bo%20apresenta%20atividade%20agonista%20parcial%20sobre%20os%20receptores%20AT1%20e%20tem%20afinidade%20muito%20maior%20(cerca%20de%2020.000%20vezes)%20para%20com%20receptores%20AT1%20do%20que%20para%20com%20receptores%20AT2.%20A%20valsartana%20n%26%23xE3%3Bo%20inibe%20a%20ECA%2C%20tamb%26%23xE9%3Bm%20conhecida%20como%20cininase%20II%2C%20que%20converte%20Ang%20I%20em%20Ang%20II%20e%20degrada%20a%20bradicinina.%20Uma%20vez%20que%20n%26%23xE3%3Bo%20existe%20efeito%20sobre%20a%20ECA%20e%20nenhuma%20potencializa%26%23xE7%3B%26%23xE3%3Bo%20da%20bradicinina%20ou%20subst%26%23xE2%3Bncia%20P%2C%20%26%23xE9%3B%20improv%26%23xE1%3Bvel%20que%20os%20antagonistas%20de%20angiotensina%20II%20estejam%20associados%20%26%23xE0%3B%20tosse.%20Em%20estudos%20cl%26%23xED%3Bnicos%20em%20que%20a%20valsartana%20foi%20comparada%20aos%20inibidores%20da%20ECA%2C%20a%20incid%26%23xEA%3Bncia%20de%20tosse%20seca%20foi%20significativamente%20menor%20(P%20%26lt%3B%200%2C05)%20em%20pacientes%20tratados%20com%20valsartana%20do%20que%20naqueles%20tratados%20com%20inibidores%20da%20ECA%20(2%2C6%25%20versus%207%2C9%25%2C%20respectivamente).%20%3Cbr%3E%20Em%20um%20estudo%20cl%26%23xED%3Bnico%20em%20pacientes%20com%20hist%26%23xF3%3Bria%20de%20tosse%20seca%20durante%20terap%26%23xEA%3Butica%20com%20inibidores%20da%20ECA%2C%2019%2C5%25%20dos%20pacientes%20que%20recebiam%20valsartana%20e%2019%2C0%25%20desses%20que%20recebiam%20um%20diur%26%23xE9%3Btico%20tiaz%26%23xED%3Bdico%20apresentaram%20epis%26%23xF3%3Bdios%20de%20tosse%2C%20comparados%20a%2068%2C5%25%20daqueles%20tratados%20com%20inibidores%20da%20ECA%20(P%20%26lt%3B%200%2C05).%20A%20valsartana%20n%26%23xE3%3Bo%20se%20liga%20ou%20bloqueia%20outros%20receptores%20hormonais%20ou%20canais%20de%20%26%23xED%3Bons%2C%20importantes%20na%20regula%26%23xE7%3B%26%23xE3%3Bo%20cardiovascular.%20%3Cbr%3E%20Hipertens%26%23xE3%3Bo%20%3Cbr%3E%20A%20administra%26%23xE7%3B%26%23xE3%3Bo%20de%20DIOVAN%20em%20pacientes%20com%20hipertens%26%23xE3%3Bo%20ocasiona%20redu%26%23xE7%3B%26%23xE3%3Bo%20da%20press%26%23xE3%3Bo%20arterial%20sem%20alterar%20a%20freq%26%23xFC%3B%26%23xEA%3Bncia%20card%26%23xED%3Baca.%20Na%20maioria%20dos%20pacientes%2C%20ap%26%23xF3%3Bs%20a%20administra%26%23xE7%3B%26%23xE3%3Bo%20de%20uma%20dose%20oral%20%26%23xFA%3Bnica%2C%20o%20in%26%23xED%3Bcio%20da%20atividade%20anti-hipertensiva%20ocorre%20dentro%20de%20duas%20horas%20e%20o%20pico%20de%20redu%26%23xE7%3B%26%23xE3%3Bo%20da%20press%26%23xE3%3Bo%20arterial%20%26%23xE9%3B%20atingido%20em%204%20%26%23x96%3B%206%20horas.%20O%20efeito%20anti-hipertensivo%20persiste%20por%2024%20horas%20ap%26%23xF3%3Bs%20a%20administra%26%23xE7%3B%26%23xE3%3Bo.%20Durante%20administra%26%23xE7%3B%26%23xF5%3Bes%20repetidas%2C%20a%20redu%26%23xE7%3B%26%23xE3%3Bo%20m%26%23xE1%3Bxima%20da%20press%26%23xE3%3Bo%20arterial%20com%20qualquer%20dose%20%26%23xE9%3B%20geralmente%20atingida%20em%202%20%26%23x96%3B%204%20semanas%20e%20se%20mant%26%23xE9%3Bm%20durante%20a%20terap%26%23xEA%3Butica%20a%20longo%20prazo.%20Em%20associa%26%23xE7%3B%26%23xE3%3Bo%20com%20hidroclorotiazida%2C%20obt%26%23xE9%3Bm-se%20uma%20redu%26%23xE7%3B%26%23xE3%3Bo%20adicional%20significativa%20na%20press%26%23xE3%3Bo%20arterial.%20A%20retirada%20abrupta%20de%20DIOVAN%20n%26%23xE3%3Bo%20foi%20associada%20com%20hipertens%26%23xE3%3Bo%20de%20rebote%20ou%20outro%20efeito%20cl%26%23xED%3Bnico%20adverso.%20Em%20estudos%20de%20doses%20m%26%23xFA%3Bltiplas%20em%20pacientes%20hipertensos%2C%20valsartana%20n%26%23xE3%3Bo%20demonstrou%20efeitos%20significativos%20sobre%20as%20dosagens%20do%20colesterol%20total%2C%20dos%20triglic%26%23xE9%3Brides%20em%20jejum%2C%20da%20glicemia%20de%20jejum%20ou%20do%20%26%23xE1%3Bcido%20%26%23xFA%3Brico.%20%3Cbr%3E%20Insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%20%3Cbr%3E%20Hemodin%26%23xE2%3Bmica%20e%20neuro-horm%26%23xF4%3Bnios.%20A%20hemodin%26%23xE2%3Bmica%20e%20os%20neuro-horm%26%23xF4%3Bnios%20plasm%26%23xE1%3Bticos%20foram%20medidos%20em%20pacientes%20com%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%20classe%20II%20%26%23x96%3B%20IV%20da%20NYHA%20(New%20York%20Heart%20Association)%20com%20press%26%23xE3%3Bo%20capilar%20pulmonar%20%26%23x2265%3B%2015%20mmHg%20em%202%20estudos%20de%20tratamento%20cr%26%23xF4%3Bnico%20de%20curta%20dura%26%23xE7%3B%26%23xE3%3Bo.%20%3Cbr%3E%20Em%20um%20estudo%2C%20que%20incluiu%20pacientes%20cronicamente%20tratados%20com%20inibidores%20da%20ECA%2C%20doses%20%26%23xFA%3Bnicas%20e%20m%26%23xFA%3Bltiplas%20de%20valsartana%20administradas%20em%20combina%26%23xE7%3B%26%23xE3%3Bo%20com%20inibidores%20da%20ECA%20melhoraram%20a%20hemodin%26%23xE2%3Bmica%2C%20incluindo%20a%20press%26%23xE3%3Bo%20capilar%20pulmonar%20(PCP)%2C%20a%20press%26%23xE3%3Bo%20diast%26%23xF3%3Blica%20da%20art%26%23xE9%3Bria%20pulmonar%20(PDAP)%20e%20a%20press%26%23xE3%3Bo%20arterial%20sist%26%23xF3%3Blica%20(PAS).%20Foi%20observada%20uma%20redu%26%23xE7%3B%26%23xE3%3Bo%20nos%20n%26%23xED%3Bveis%20da%20aldosterona%20plasm%26%23xE1%3Btica%20(AP)%20e%20da%20noradrenalina%20plasm%26%23xE1%3Btica%20(NP)%20ap%26%23xF3%3Bs%2028%20dias%20de%20tratamento.%20No%20segundo%20estudo%2C%20que%20incluiu%20somente%20pacientes%20n%26%23xE3%3Bo%20tratados%20com%20inibidores%20da%20ECA%20por%20pelo%20menos%206%20meses%20antes%20da%20inclus%26%23xE3%3Bo%2C%20a%20valsartana%20melhorou%20significativamente%20a%20PCP%2C%20a%20resist%26%23xEA%3Bncia%20vascular%20sist%26%23xEA%3Bmica%20(RVS)%2C%20o%20d%26%23xE9%3Bbito%20card%26%23xED%3Baco%20(DC)%20e%20a%20PAS%20ap%26%23xF3%3Bs%2028%20dias%20de%20tratamento.%20No%20estudo%20a%20longo%20prazo%20Val-HeFT%2C%20a%20noradrenalina%20plasm%26%23xE1%3Btica%20e%20o%20pept%26%23xED%3Bdeo%20cerebral%20natriur%26%23xE9%3Btico%20(PCN)%20foram%20significativamente%20reduzidos%20em%20rela%26%23xE7%3B%26%23xE3%3Bo%20a%20fase%20inicial%20no%20grupo%20valsartana%20quando%20comparado%20ao%20placebo.%20%3Cbr%3E%20Morbidade%20e%20mortalidade.%20%3Cbr%3E%20O%20Val-HeFT%20foi%20um%20estudo%20multinacional%2C%20randomizado%20e%20controlado%20onde%20se%20comparou%20valsartana%20ao%20placebo%20na%20morbidade%20e%20mortalidade%20de%20pacientes%20com%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%20classe%20II%20(62%25)%2C%20III%20(36%25)%20e%20IV%20(2%25)%20da%20NYHA%20recebendo%20terap%26%23xEA%3Butica%20usual%20e%20com%20fra%26%23xE7%3B%26%23xE3%3Bo%20de%20eje%26%23xE7%3B%26%23xE3%3Bo%20do%20ventr%26%23xED%3Bculo%20esquerdo%20(FEVE)%20%26lt%3B%2040%25%20e%20di%26%23xE2%3Bmetro%20diast%26%23xF3%3Blico%20interno%20do%20ventr%26%23xED%3Bculo%20esquerdo%20(DDIVE)%20%26gt%3B%202.9%20cm%2Fm2.%20Foram%20inclu%26%23xED%3Bdos%205.010%20pacientes%20no%20estudo%20em%2016%20pa%26%23xED%3Bses%2C%20que%20foram%20randomizados%20para%20receber%20DIOVAN%20ou%20placebo%20em%20adi%26%23xE7%3B%26%23xE3%3Bo%20%26%23xE0%3B%20todas%20as%20outras%20terap%26%23xEA%3Buticas%20apropriadas%20incluindo%20os%20inibidores%20da%20ECA%20(93%25)%2C%20os%20diur%26%23xE9%3Bticos%20(86%25)%2C%20a%20digoxina%20(67%25)%20e%20os%20betabloqueadores%20(36%25).%20A%20dura%26%23xE7%3B%26%23xE3%3Bo%20m%26%23xE9%3Bdia%20do%20acompanhamento%20foi%20de%20aproximadamente%20dois%20anos.%20A%20dose%20m%26%23xE9%3Bdia%20di%26%23xE1%3Bria%20de%20DIOVAN%20no%20estudo%20Val-HeFT%20foi%20de%20254%20mg.%20%3Cbr%3E%20O%20estudo%20teve%202%20desfechos%20prim%26%23xE1%3Brios%3A%20mortalidade%20por%20todas%20as%20causas%20(tempo%20at%26%23xE9%3B%20o%20%26%23xF3%3Bbito)%20e%20a%20morbidade%20da%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%20(tempo%20at%26%23xE9%3B%20o%20primeiro%20evento%20m%26%23xF3%3Brbido)%20definido%20como%20morte%2C%20morte%20s%26%23xFA%3Bbita%20com%20ressuscita%26%23xE7%3B%26%23xE3%3Bo%2C%20hospitaliza%26%23xE7%3B%26%23xE3%3Bo%20por%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%2C%20ou%20administra%26%23xE7%3B%26%23xE3%3Bo%20intravenosa%20de%20drogas%20inotr%26%23xF3%3Bpicas%20ou%20vasodilatadoras%20por%20quatro%20horas%20ou%20mais%20sem%20hospitaliza%26%23xE7%3B%26%23xE3%3Bo.%20Mortalidade%20por%20todas%20as%20causas%20foi%20similar%20nos%20grupos%20tratados%20com%20valsartana%20e%20com%20placebo.%20A%20morbidade%20foi%20significativamente%20reduzida%20em%2013%2C2%25%20com%20a%20valsartana%20comparado%20ao%20placebo.%20O%20principal%20benef%26%23xED%3Bcio%20foi%20uma%20redu%26%23xE7%3B%26%23xE3%3Bo%20de%2027%2C5%25%20no%20risco%20para%20o%20tempo%20at%26%23xE9%3B%20a%20primeira%20hospitaliza%26%23xE7%3B%26%23xE3%3Bo%20por%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca.%20%3Cbr%3E%20Os%20maiores%20benef%26%23xED%3Bcios%20foram%20nos%20pacientes%20que%20n%26%23xE3%3Bo%20estavam%20recebendo%20um%20inibidor%20da%20ECA%20ou%20um%20betabloqueador.%20Entretanto%2C%20redu%26%23xE7%3B%26%23xF5%3Bes%20de%20risco%20favorecendo%20o%20placebo%20foram%20observadas%20para%20aqueles%20pacientes%20tratados%20com%20a%20tripla%20combina%26%23xE7%3B%26%23xE3%3Bo%20de%20um%20betabloqueador%2C%20um%20inibidor%20da%20ECA%20e%20um%20bloqueador%20do%20receptor%20de%20angiotensina%20II%2C%20valsartana.%20Estudos%20adicionais%20como%20o%20VALIANT%20(vide%20%26%23x93%3BP%26%23xF3%3Bs-infarto%20do%20mioc%26%23xE1%3Brdio%26%23x94%3B)%2C%20nos%20quais%20a%20mortalidade%20n%26%23xE3%3Bo%20foi%20aumentada%20nesses%20pacientes%2C%20reduziram%20as%20preocupa%26%23xE7%3B%26%23xF5%3Bes%20em%20rela%26%23xE7%3B%26%23xE3%3Bo%20%26%23xE0%3B%20tripla%20combina%26%23xE7%3B%26%23xE3%3Bo.%20Capacidade%20e%20toler%26%23xE2%3Bncia%20ao%20exerc%26%23xED%3Bcio.%20%3Cbr%3E%20Os%20efeitos%20da%20valsartana%20em%20adi%26%23xE7%3B%26%23xE3%3Bo%20%26%23xE0%3B%20terap%26%23xEA%3Butica%20usual%20da%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%20na%20toler%26%23xE2%3Bncia%20ao%20exerc%26%23xED%3Bcio%20usando%20o%20Protocolo%20Modificado%20de%20Naughton%20foram%20medidos%20em%20pacientes%20com%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%20da%20classe%20II%20%26%23x96%3B%20IV%20da%20NYHA%20com%20disfun%26%23xE7%3B%26%23xE3%3Bo%20ventricular%20esquerda%20(FEVE%20%26lt%3B%2040%25%20).%20O%20aumento%20do%20tempo%20de%20exerc%26%23xED%3Bcio%20em%20rela%26%23xE7%3B%26%23xE3%3Bo%20%26%23xE0%3B%20fase%20inicial%20foi%20observado%20para%20todos%20os%20grupos%20do%20tratamento.%20Aumentos%20m%26%23xE9%3Bdios%20maiores%20em%20rela%26%23xE7%3B%26%23xE3%3Bo%20%26%23xE0%3B%20fase%20inicial%20no%20tempo%20de%20exerc%26%23xED%3Bcio%20foram%20observados%20para%20o%20grupo%20valsartana%20comparado%20ao%20grupo%20placebo%2C%20embora%20n%26%23xE3%3Bo%20tenha%20atingido%20signific%26%23xE2%3Bncia%20estat%26%23xED%3Bstica.%20%3Cbr%3E%20As%20melhoras%20mais%20importantes%20foram%20observadas%20no%20subgrupo%20dos%20pacientes%20que%20n%26%23xE3%3Bo%20estavam%20recebendo%20terap%26%23xEA%3Butica%20com%20inibidor%20da%20ECA%2C%20nos%20quais%20as%20varia%26%23xE7%3B%26%23xF5%3Bes%20m%26%23xE9%3Bdias%20no%20tempo%20de%20exerc%26%23xED%3Bcio%20foram%202%20vezes%20maiores%20para%20o%20grupo%20valsartana%20comparado%20ao%20grupo%20placebo.%20Os%20efeitos%20da%20valsartana%20comparados%20aos%20do%20enalapril%20na%20capacidade%20ao%20exerc%26%23xED%3Bcio%20utilizando%20o%20teste%20da%20caminhada%20de%20seis%20minutos%20foram%20determinados%20nos%20pacientes%20com%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%20classe%20II%20e%20III%20da%20NYHA%20e%20com%20fra%26%23xE7%3B%26%23xE3%3Bo%20de%20eje%26%23xE7%3B%26%23xE3%3Bo%20do%20ventr%26%23xED%3Bculo%20esquerdo%20%26lt%3B%2045%25%20que%20estavam%20recebendo%20terap%26%23xEA%3Butica%20com%20inibidor%20da%20ECA%20por%20pelo%20menos%203%20meses%20antes%20do%20in%26%23xED%3Bcio%20do%20estudo.%20A%20valsartana%2080%20mg%20a%20160%20mg%20uma%20vez%20ao%20dia%20foi%20t%26%23xE3%3Bo%20eficaz%20quanto%20enalapril%205%20mg%20a%2010%20mg%20duas%20vezes%20ao%20dia%2C%20com%20refer%26%23xEA%3Bncia%20%26%23xE0%3B%20capacidade%20ao%20exerc%26%23xED%3Bcio%2C%20conforme%20avaliado%20pelo%20teste%20da%20caminhada%20dos%20seis%20minutos%20nos%20pacientes%20estabilizados%20previamente%20com%20inibidores%20da%20ECA%20e%20diretamente%20substitu%26%23xED%3Bdos%20para%20valsartana%20ou%20enalapril.%20%3Cbr%3E%20Classe%20da%20NYHA%2C%20sinais%20e%20sintomas%2C%20qualidade%20de%20vida%20e%20fra%26%23xE7%3B%26%23xE3%3Bo%20de%20eje%26%23xE7%3B%26%23xE3%3Bo.%20%3Cbr%3E%20No%20estudo%20cl%26%23xED%3Bnico%20Val-HeFT%2C%20os%20pacientes%20tratados%20com%20valsartana%20demonstraram%20uma%20melhora%20significativa%20na%20classe%20da%20NYHA%20e%20nos%20sinais%20e%20sintomas%20de%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%2C%20incluindo%20dispn%26%23xE9%3Bia%2C%20fadiga%2C%20edema%20e%20estertores%20(percebidos%20na%20ausculta%20do%20t%26%23xF3%3Brax)%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20ao%20placebo.%20Os%20pacientes%20tratados%20com%20valsartana%20tiveram%20uma%20melhor%20qualidade%20de%20vida%20como%20demonstrado%20pelas%20mudan%26%23xE7%3Bas%20na%20pontua%26%23xE7%3B%26%23xE3%3Bo%20do%20question%26%23xE1%3Brio%20%26%23x93%3BMinnesota%20Living%20with%20Heart%20Failure%20Quality%20of%20Life%26%23x94%3B%20em%20rela%26%23xE7%3B%26%23xE3%3Bo%20ao%20placebo.%20A%20fra%26%23xE7%3B%26%23xE3%3Bo%20de%20eje%26%23xE7%3B%26%23xE3%3Bo%20em%20pacientes%20tratados%20com%20valsartana%20aumentou%20significativamente%20e%20o%20DDIVE%20foi%20reduzido%20significativamente%20no%20desfecho%20em%20rela%26%23xE7%3B%26%23xE3%3Bo%20%26%23xE0%3B%20fase%20inicial%20quando%20comparado%20ao%20placebo.%20%3Cbr%3E%20P%26%23xF3%3Bs-infarto%20do%20mioc%26%23xE1%3Brdio%20%3Cbr%3E%20O%20estudo%20de%20valsartana%20no%20infarto%20agudo%20do%20mioc%26%23xE1%3Brdio%20(VALIANT)%20foi%20randomizado%2C%20controlado%2C%20multinacional%20e%20duplo-cego%20em%2014.703%20pacientes%20com%20infarto%20do%20mioc%26%23xE1%3Brdio%20agudo%20e%20sinais%2C%20sintomas%20ou%20evid%26%23xEA%3Bncia%20radiol%26%23xF3%3Bgica%20de%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%20congestiva%20e%2Fou%20evid%26%23xEA%3Bncia%20de%20disfun%26%23xE7%3B%26%23xE3%3Bo%20sist%26%23xF3%3Blica%20do%20ventr%26%23xED%3Bculo%20esquerdo%20(manifestado%20como%20uma%20fra%26%23xE7%3B%26%23xE3%3Bo%20de%20eje%26%23xE7%3B%26%23xE3%3Bo%20%26%23x2264%3B%2040%25%20por%20ventriculografia%20por%20radionucl%26%23xED%3Bdeos%20ou%20%26%23x2264%3B%2035%25%20por%20ecocardiografia%20ou%20angiografia%20ventricular%20de%20contraste).%20Os%20pacientes%20foram%20randomizados%20dentro%20de%2012%20horas%20a%2010%20dias%20ap%26%23xF3%3Bs%20o%20in%26%23xED%3Bcio%20dos%20sintomas%20de%20infarto%20do%20mioc%26%23xE1%3Brdio%20em%20um%20dos%20tr%26%23xEA%3Bs%20grupos%20de%20tratamento%3A%20valsartana%20(titulada%20a%20partir%20de%2020%20mg%20duas%20vezes%20ao%20dia%20para%20a%20maior%20dose%20tolerada%20at%26%23xE9%3B%20um%20m%26%23xE1%3Bximo%20de%20160%20mg%20duas%20vezes%20ao%20dia)%2C%20o%20inibidor%20de%20ECA%20captopril%20(titulado%20a%20partir%20de%206%2C25%20mg%20tr%26%23xEA%3Bs%20vezes%20ao%20dia%20para%20a%20maior%20dose%20tolerada%20at%26%23xE9%3B%20um%20m%26%23xE1%3Bximo%20de%2050%20mg%20tr%26%23xEA%3Bs%20vezes%20ao%20dia)%20ou%20a%20combina%26%23xE7%3B%26%23xE3%3Bo%20de%20valsartana%20mais%20captopril.%20No%20grupo%20de%20combina%26%23xE7%3B%26%23xE3%3Bo%2C%20a%20dose%20de%20valsartana%20foi%20titulada%20a%20partir%20de%2020%20mg%20duas%20vezes%20ao%20dia%20para%20a%20maior%20dose%20tolerada%20at%26%23xE9%3B%20um%20m%26%23xE1%3Bximo%20de%2080%20mg%20duas%20vezes%20ao%20dia%3B%20a%20dose%20de%20captopril%20foi%20a%20mesma%20para%20monoterapia.%20A%20dura%26%23xE7%3B%26%23xE3%3Bo%20m%26%23xE9%3Bdia%20do%20tratamento%20foi%20de%20dois%20anos.%20A%20dose%20di%26%23xE1%3Bria%20m%26%23xE9%3Bdia%20de%20DIOVAN%20no%20grupo%20de%20monoterapia%20foi%20de%20217%20mg.%20A%20terap%26%23xEA%3Butica%20basal%20incluiu%20%26%23xE1%3Bcido%20acetilsalic%26%23xED%3Blico%20(91%25)%2C%20betabloqueadores%20(70%25)%2C%20inibidores%20da%20ECA%20(40%25)%2C%20trombol%26%23xED%3Bticos%20(35%25)%20e%20estatinas%20(34%25).%20A%20popula%26%23xE7%3B%26%23xE3%3Bo%20estudada%20foi%20de%2069%25%20de%20homens%2C%2094%25%20de%20caucasianos%20e%2053%25%20com%2065%20anos%20de%20idade%20ou%20mais%20velhos.%20%3Cbr%3E%20O%20desfecho%20prim%26%23xE1%3Brio%20foi%20o%20tempo%20para%20a%20mortalidade%20por%20todas%20as%20causas.%20A%20valsartana%20foi%20pelo%20menos%20t%26%23xE3%3Bo%20efetiva%20quanto%20o%20captopril%20na%20redu%26%23xE7%3B%26%23xE3%3Bo%20da%20mortalidade%20por%20todas%20as%20causas%20p%26%23xF3%3Bs-infarto%20do%20mioc%26%23xE1%3Brdio.%20A%20mortalidade%20por%20todas%20as%20causas%20foi%20similar%20nos%20grupos%20de%20valsartana%20(19%2C9%20%25)%2C%20captopril%20(19%2C5%25)%20e%20valsartana%20%2B%20captopril%20(19%2C3%25).%20A%20valsartana%20foi%20tamb%26%23xE9%3Bm%20efetiva%20na%20prolonga%26%23xE7%3B%26%23xE3%3Bo%20do%20tempo%20para%20redu%26%23xE7%3B%26%23xE3%3Bo%20da%20mortalidade%20cardiovascular%2C%20hospitaliza%26%23xE7%3B%26%23xE3%3Bo%20por%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%2C%20infarto%20do%20mioc%26%23xE1%3Brdio%20recorrente%2C%20parada%20card%26%23xED%3Baca%20ressuscitada%20e%20em%20acidente%20vascular%20cerebral%20n%26%23xE3%3Bo-fatal%20(desfecho%20composto%20secund%26%23xE1%3Brio).%20Uma%20vez%20que%20este%20foi%20um%20estudo%20com%20um%20controle%20ativo%20(captopril)%2C%20uma%20an%26%23xE1%3Blise%20adicional%20da%20mortalidade%20por%20todas%20as%20causas%20foi%20realizada%20para%20estimar%20o%20quanto%20a%20valsartana%20desempenhou%20versus%20placebo.%20Usando%20os%20resultados%20das%20refer%26%23xEA%3Bncias%20pr%26%23xE9%3Bvias%20dos%20estudos%20do%20infarto%20do%20mioc%26%23xE1%3Brdio%20%26%23x96%3B%20SAVE%2C%20AIRE%20e%20TRACE%20%26%23x96%3B%20o%20efeito%20estimado%20da%20valsartana%20preservou%2099%2C6%25%20do%20efeito%20do%20captopril%20(97%2C5%20%25%20CI%20%3D%2060%20%26%23x96%3B%20139%25).%20Combinar%20valsartana%20com%20captopril%20n%26%23xE3%3Bo%20adicionou%20mais%20benef%26%23xED%3Bcios%20sobre%20o%20captopril%20isolado.%20N%26%23xE3%3Bo%20houve%20diferen%26%23xE7%3Ba%20na%20mortalidade%20por%20todas%20as%20causas%20com%20base%20na%20idade%2C%20sexo%2C%20ra%26%23xE7%3Ba%2C%20terap%26%23xEA%3Buticas%20basais%20ou%20doen%26%23xE7%3Ba%20de%20base.%20N%26%23xE3%3Bo%20houve%20diferen%26%23xE7%3Ba%20na%20mortalidade%20por%20todas%20as%20causas%20ou%20mortalidade%20cardiovascular%20ou%20morbidade%20quando%20betabloqueadores%20foram%20administrados%20juntos%20com%20a%20combina%26%23xE7%3B%26%23xE3%3Bo%20de%20valsartana%20%2B%20captopril%2C%20valsartana%20isolada%20ou%20captopril%20isolado.%20Independentemente%20do%20tratamento%20da%20droga%20estudada%2C%20a%20mortalidade%20foi%20maior%20no%20grupo%20de%20pacientes%20n%26%23xE3%3Bo%20tratados%20com%20um%20betabloqueador%2C%20sugerindo%20que%20o%20conhecido%20benef%26%23xED%3Bcio%20do%20betabloqueador%20nesta%20popula%26%23xE7%3B%26%23xE3%3Bo%20foi%20mantido%20neste%20estudo.%20Al%26%23xE9%3Bm%20disto%2C%20os%20benef%26%23xED%3Bcios%20do%20tratamento%20da%20combina%26%23xE7%3B%26%23xE3%3Bo%20de%20valsartana%20%2B%20captopril%2C%20monoterapia%20de%20valsartana%20e%20monoterapia%20de%20captopril%20foram%20mantidos%20em%20pacientes%20tratados%20com%20betabloqueadores.%20%3Cbr%3E%20Farmacocin%26%23xE9%3Btica%20%3Cbr%3E%20A%20absor%26%23xE7%3B%26%23xE3%3Bo%20de%20valsartana%20ap%26%23xF3%3Bs%20administra%26%23xE7%3B%26%23xE3%3Bo%20oral%20%26%23xE9%3B%20r%26%23xE1%3Bpida%2C%20embora%20a%20quantidade%20absorvida%20varie%20amplamente.%20A%20biodisponibilidade%20absoluta%20m%26%23xE9%3Bdia%20para%20DIOVAN%20%26%23xE9%3B%20de%2023%25.%20Valsartana%20apresenta%20um%20decaimento%20cin%26%23xE9%3Btico%20multiexponencial%20(t1%2F2%20alfa%20%26lt%3B%201h%20e%20t1%2F2%20beta%20cerca%20de%209%20h).%20A%20farmacocin%26%23xE9%3Btica%20de%20valsartana%20%26%23xE9%3B%20linear%20no%20intervalo%20de%20dose%20testada.%20N%26%23xE3%3Bo%20ocorrem%20altera%26%23xE7%3B%26%23xF5%3Bes%20na%20cin%26%23xE9%3Btica%20de%20valsartana%20em%20administra%26%23xE7%3B%26%23xF5%3Bes%20repetidas%20e%20h%26%23xE1%3B%20pouco%20ac%26%23xFA%3Bmulo%20quando%20administrado%20uma%20vez%20ao%20dia.%20As%20concentra%26%23xE7%3B%26%23xF5%3Bes%20plasm%26%23xE1%3Bticas%20observadas%20foram%20similares%20em%20homens%20e%20mulheres.%20A%20valsartana%20tem%20alta%20taxa%20de%20liga%26%23xE7%3B%26%23xE3%3Bo%20%26%23xE0%3Bs%20prote%26%23xED%3Bnas%20s%26%23xE9%3Bricas%20(94%20%26%23x96%3B%2097%25)%2C%20principalmente%20a%20albumina%20s%26%23xE9%3Brica.%20O%20volume%20de%20distribui%26%23xE7%3B%26%23xE3%3Bo%20no%20steady-state%20(estado%20de%20equil%26%23xED%3Bbrio)%20%26%23xE9%3B%20baixo%20(cerca%20de%2017%20litros).%20%3Cbr%3E%20O%20clearance%20(depura%26%23xE7%3B%26%23xE3%3Bo)%20plasm%26%23xE1%3Btico%20%26%23xE9%3B%20relativamente%20lento%20(cerca%20de%202%20L%2Fh)%20quando%20comparado%20a%20circula%26%23xE7%3B%26%23xE3%3Bo%20sang%26%23xFC%3B%26%23xED%3Bnea%20hep%26%23xE1%3Btica%20(cerca%20de%2030%20L%2Fh).%20Do%20total%20da%20dose%20absorvida%2C%2070%25%20s%26%23xE3%3Bo%20excretados%20nas%20fezes%20e%2030%25%20na%20urina%2C%20principalmente%20como%20composto%20inalterado.%20Quando%20DIOVAN%20%26%23xE9%3B%20administrado%20com%20alimentos%2C%20a%20%26%23xE1%3Brea%20sob%20a%20curva%20de%20concentra%26%23xE7%3B%26%23xE3%3Bo%20plasm%26%23xE1%3Btica%20(AUC)%20de%20valsartana%20sofre%20redu%26%23xE7%3B%26%23xE3%3Bo%20de%2048%25%2C%20embora%20cerca%20de%208%20horas%20ap%26%23xF3%3Bs%20a%20administra%26%23xE7%3B%26%23xE3%3Bo%2C%20as%20concentra%26%23xE7%3B%26%23xF5%3Bes%20plasm%26%23xE1%3Bticas%20de%20valsartana%20sejam%20similares%20em%20pacientes%20que%20ingeriram%20o%20produto%20em%20jejum%20ou%20com%20alimentos.%20Entretanto%2C%20esta%20redu%26%23xE7%3B%26%23xE3%3Bo%20da%20AUC%2C%20n%26%23xE3%3Bo%20se%20acompanha%20de%20redu%26%23xE7%3B%26%23xE3%3Bo%20clinicamente%20significativa%20nos%20efeitos%20terap%26%23xEA%3Buticos%2C%20podendo%20o%20DIOVAN%20ser%20administrado%20com%20ou%20sem%20alimentos.%20O%20tempo%20m%26%23xE9%3Bdio%20para%20o%20pico%20de%20concentra%26%23xE7%3B%26%23xE3%3Bo%20e%20a%20meia-vida%20de%20elimina%26%23xE7%3B%26%23xE3%3Bo%20da%20valsartana%20em%20pacientes%20com%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%20%26%23xE9%3B%20similar%20ao%20observado%20em%20pacientes%20sadios.%20Os%20valores%20AUC%20e%20Cmax%20da%20valsartana%20aumentam%20linearmente%20e%20s%26%23xE3%3Bo%20praticamente%20proporcionais%20com%20o%20aumento%20da%20dose%20dentro%20da%20faixa%20cl%26%23xED%3Bnica%20(40%20a%20160%20mg%20duas%20vezes%20ao%20dia).%20O%20fator%20de%20acumula%26%23xE7%3B%26%23xE3%3Bo%20m%26%23xE9%3Bdio%20%26%23xE9%3B%20aproximadamente%201%2C7.%20A%20depura%26%23xE7%3B%26%23xE3%3Bo%20aparente%20da%20valsartana%20ap%26%23xF3%3Bs%20uma%20administra%26%23xE7%3B%26%23xE3%3Bo%20oral%20%26%23xE9%3B%20aproximadamente%204%2C5%20L%2Fh.%20A%20idade%20n%26%23xE3%3Bo%20afeta%20a%20depura%26%23xE7%3B%26%23xE3%3Bo%20aparente%20em%20pacientes%20com%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca.%20%3Cbr%3E%20Popula%26%23xE7%3B%26%23xF5%3Bes%20especiais%20de%20pacientes%20%3Cbr%3E%20Pacientes%20idosos%20Maior%20exposi%26%23xE7%3B%26%23xE3%3Bo%20sist%26%23xEA%3Bmica%20%26%23xE0%3B%20valsartana%20foi%20observada%20em%20indiv%26%23xED%3Bduos%20idosos%20comparados%20com%20indiv%26%23xED%3Bduos%20jovens%3B%20entretanto%2C%20isso%20n%26%23xE3%3Bo%20apresentou%20nenhum%20significado%20cl%26%23xED%3Bnico.%20%3Cbr%3E%20Pacientes%20com%20insufici%26%23xEA%3Bncia%20renal%20Como%20esperado%20para%20um%20composto%20no%20qual%20o%20clearance%20(depura%26%23xE7%3B%26%23xE3%3Bo)%20renal%20contribui%20com%20apenas%2030%25%20do%20clearance%20(depura%26%23xE7%3B%26%23xE3%3Bo)%20plasm%26%23xE1%3Btico%20total%2C%20n%26%23xE3%3Bo%20existe%20correla%26%23xE7%3B%26%23xE3%3Bo%20entre%20a%20fun%26%23xE7%3B%26%23xE3%3Bo%20renal%20e%20a%20exposi%26%23xE7%3B%26%23xE3%3Bo%20sist%26%23xEA%3Bmica%20%26%23xE0%3B%20valsartana.%20Portanto%2C%20n%26%23xE3%3Bo%20%26%23xE9%3B%20necess%26%23xE1%3Brio%20ajuste%20de%20dose%20em%20pacientes%20com%20insufici%26%23xEA%3Bncia%20renal.%20Nenhum%20estudo%20foi%20realizado%20em%20pacientes%20sob%20di%26%23xE1%3Blise.%20No%20entanto%2C%20valsartana%20possui%20alta%20taxa%20de%20liga%26%23xE7%3B%26%23xE3%3Bo%20%26%23xE0%3Bs%20prote%26%23xED%3Bnas%20plasm%26%23xE1%3Bticas%2C%20sendo%20improv%26%23xE1%3Bvel%20sua%20remo%26%23xE7%3B%26%23xE3%3Bo%20por%20di%26%23xE1%3Blise.%20%3Cbr%3E%20Pacientes%20com%20insufici%26%23xEA%3Bncia%20hep%26%23xE1%3Btica%20Cerca%20de%2070%25%20da%20dose%20absorvida%20s%26%23xE3%3Bo%20excretados%20na%20bile%2C%20principalmente%20como%20composto%20inalterado.%20Valsartana%20n%26%23xE3%3Bo%20sofre%20biotransforma%26%23xE7%3B%26%23xE3%3Bo%20extensa%20e%2C%20como%20esperado%2C%20a%20exposi%26%23xE7%3B%26%23xE3%3Bo%20sist%26%23xEA%3Bmica%20%26%23xE0%3B%20valsartana%20n%26%23xE3%3Bo%20se%20relaciona%20com%20o%20grau%20de%20disfun%26%23xE7%3B%26%23xE3%3Bo%20hep%26%23xE1%3Btica.%20Portanto%2C%20nenhum%20ajuste%20de%20dose%20%26%23xE9%3B%20necess%26%23xE1%3Brio%20em%20pacientes%20com%20insufici%26%23xEA%3Bncia%20hep%26%23xE1%3Btica%20de%20origem%20n%26%23xE3%3Bo%20biliar%20e%20sem%20colestase.%20Observou-se%20que%20a%20AUC%20da%20valsartana%20%26%23xE9%3B%20aproximadamente%20o%20dobro%20em%20pacientes%20com%20cirrose%20biliar%20ou%20obstru%26%23xE7%3B%26%23xE3%3Bo%20biliar.%20(vide%20%26%23x93%3BPrecau%26%23xE7%3B%26%23xF5%3Bes%20e%20Advert%26%23xEA%3Bncias%26%23x94%3B).%20%3Cbr%3E%20Dados%20de%20seguran%26%23xE7%3Ba%20pr%26%23xE9%3B-cl%26%23xED%3Bnicos%20%3Cbr%3E%20Em%20diversos%20estudos%20pr%26%23xE9%3B-cl%26%23xED%3Bnicos%20de%20seguran%26%23xE7%3Ba%20realizados%20com%20v%26%23xE1%3Brias%20esp%26%23xE9%3Bcies%20de%20animais%2C%20n%26%23xE3%3Bo%20houve%20evid%26%23xEA%3Bncia%20de%20toxicidade%20sist%26%23xEA%3Bmica%20ou%20em%20%26%23xF3%3Brg%26%23xE3%3Bos-alvo%2C%20excluindo-se%20toxicidade%20fetal%20em%20coelhos.%20Proles%20de%20ratos%20descendentes%20de%20ratas%20que%20receberam%20600%20mg%2Fkg%20durante%20o%20%26%23xFA%3Bltimo%20trimestre%20de%20gravidez%20e%20durante%20a%20lacta%26%23xE7%3B%26%23xE3%3Bo%20mostraram%20%26%23xED%3Bndice%20de%20sobreviv%26%23xEA%3Bncia%20levemente%20reduzido%2C%20bem%20como%20leve%20retardo%20no%20desenvolvimento%20(vide%20%26%23x93%3BGravidez%20e%20lacta%26%23xE7%3B%26%23xE3%3Bo%26%23x94%3B).%20Os%20principais%20achados%20pr%26%23xE9%3B-cl%26%23xED%3Bnicos%20de%20seguran%26%23xE7%3Ba%20s%26%23xE3%3Bo%20atribu%26%23xED%3Bdos%20%26%23xE0%3B%20a%26%23xE7%3B%26%23xE3%3Bo%20farmacol%26%23xF3%3Bgica%20do%20f%26%23xE1%3Brmaco%20e%20n%26%23xE3%3Bo%20demonstraram%20qualquer%20significado%20cl%26%23xED%3Bnico.%20N%26%23xE3%3Bo%20houve%20evid%26%23xEA%3Bncia%20de%20mutagenicidade%2C%20clastogenicidade%20ou%20carcinogenicidade%20em%20camundongos%20e%20ratos.%20%3Cbr%3E%3C%2Fp%3E%0A%3Ch2%3EResultados%20de%20eficacia%3C%2Fh2%3E%0A%3Cp%3EInforma%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20dispon%26%23xED%3Bvel%20para%20esta%20bula.%3C%2Fp%3E%0A%3Ch2%3EUsos%20em%20idosos%2C%20crian%26%23xE7%3Bas%20e%20em%20outros%20grupos%20de%20risco%3C%2Fh2%3E%0A%3Cp%3EInforma%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20dispon%26%23xED%3Bvel%20para%20esta%20bula.%3C%2Fp%3E%0A%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%3C%2Famp-ad%3E%0A%3Ch2%3EArmazenagem%3C%2Fh2%3E%0A%3Cp%3EInforma%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20dispon%26%23xED%3Bvel%20para%20esta%20bula.%3C%2Fp%3E%0A%3Ch2%3EDizeres%20legais%3C%2Fh2%3E%0A%3Cp%3EVENDA%20SOB%20PRESCRI%26%23xC7%3B%26%23xC3%3BO%20M%26%23xC9%3BDICA%3Cbr%3E%20Reg.%20MS%20%26%23x2013%3B%201.0068.0065%3Cbr%3E%20Farm.%20Resp.%3A%20Marco%20A.%20J.%20Siqueira%3Cbr%3E%20CRF-SP%20n%26%23xBA%3B%2023.873%3Cbr%3E%20Lote%2C%20data%20de%20fabrica%26%23xE7%3B%26%23xE3%3Bo%20e%20de%20validade%3A%20vide%20cartucho%3Cbr%3E%20Fabricado%20por%3A%20Novartis%20Pharma%20AG%2C%20Stein%2C%20Su%26%23xED%3B%26%23xE7%3Ba.%3Cbr%3E%20Importado%20por%3A%20Novartis%20Bioci%26%23xEA%3Bncias%20S.A.%3Cbr%3E%20Av.%20Ibirama%2C%20518%20%26%23x2013%3B%20Complexos%20441%2F3%3Cbr%3E%20Tabo%26%23xE3%3Bo%20da%20Serra%20%26%23x2013%3B%20SP%3Cbr%3E%20CNPJ%20n%26%23xB0%3B%2056.994.502%2F0098-62%3Cbr%3E%20Ind%26%23xFA%3Bstria%20Brasileira%3Cbr%3E%20%26%23xAE%3B%20%3D%20Marca%20registrada%20de%20Novartis%20AG%2C%20Basil%26%23xE9%3Bia%2C%20Su%26%23xED%3B%26%23xE7%3Ba.%3Cbr%3E%20BPI%2019.10.06%20%2B%20MS%2001.09.08%3Cbr%3E%202006-PSB%2FGLC-0032-s%3Cbr%3E%3C%2Fp%3E%0A%3Ch2%3EDIOVAN%20%26%23x2013%3B%20Bula%20para%20o%20paciente%3C%2Fh2%3E%0A%3Cp%3EA%26%23xE7%3B%26%23xE3%3Bo%20esperada%20do%20medicamento%3A%20DIOVAN%20%26%23xE9%3B%20utilizado%20para%20os%20tratamentos%20de%3Cbr%3E%20press%26%23xE3%3Bo%20alta%2C%20insufici%26%23xEA%3Bncia%20card%26%23xED%3Baca%20e%20p%26%23xF3%3Bs-infarto%20do%20mioc%26%23xE1%3Brdio%20em%20pacientes%20recebendo%20terap%26%23xEA%3Butica%20usual.%3Cbr%3E%20Cuidados%20de%20armazenamento%3A%20Conservar%20em%20temperatura%20ambiente%20(15%26%23xBA%3BC%20a%2030%26%23xBA%3BC).%3Cbr%3E%20Proteger%20da%20umidade.%3Cbr%3E%20Prazo%20de%20validade%3A%20A%20data%20de%20validade%20est%26%23xE1%3B%20impressa%20no%20cartucho.%20N%26%23xE3%3Bo%20utilize%20o%3Cbr%3E%20produto%20ap%26%23xF3%3Bs%20a%20data%20de%20validade.%3Cbr%3E%20Gravidez%20e%20lacta%26%23xE7%3B%26%23xE3%3Bo%3A%20Informe%20imediatamente%20ao%20seu%20m%26%23xE9%3Bdico%20sobre%20a%20ocorr%26%23xEA%3Bncia%20de%3Cbr%3E%20gravidez%20na%20vig%26%23xEA%3Bncia%20do%20tratamento%20ou%20ap%26%23xF3%3Bs%20o%20seu%20t%26%23xE9%3Brmino.%20Informe%20ao%20seu%20m%26%23xE9%3Bdico%20se%20estiver%20amamentando.%3Cbr%3E%20Cuidados%20de%20administra%26%23xE7%3B%26%23xE3%3Bo%3A%20DIOVAN%20deve%20ser%20ingerido%20de%20prefer%26%23xEA%3Bncia%20pela%20manh%26%23xE3%3B%20com%20o%20aux%26%23xED%3Blio%20de%20um%20l%26%23xED%3Bquido%2C%20com%20ou%20sem%20alimentos.%20Se%20voc%26%23xEA%3B%20se%20esquecer%20de%20tomar%20uma%20dose%2C%20retorne%20ao%20seu%20esquema%20de%20tratamento.%20N%26%23xE3%3Bo%20tome%20a%20dose%20dobrada%20(dois%20comprimidos%20de%20uma%20%26%23xFA%3Bnica%20vez).%20Siga%20a%20orienta%26%23xE7%3B%26%23xE3%3Bo%20do%20seu%20m%26%23xE9%3Bdico%2C%20respeitando%20sempre%20os%20hor%26%23xE1%3Brios%2C%20as%20doses%20e%20a%20dura%26%23xE7%3B%26%23xE3%3Bo%20do%20tratamento.%20Interrup%26%23xE7%3B%26%23xE3%3Bo%20do%20tratamento%3A%20N%26%23xE3%3Bo%20interromper%20o%20tratamento%20sem%20o%20conhecimento%20do%20seu%20m%26%23xE9%3Bdico.%20Rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%3A%20DIOVAN%20pode%20causar%20rea%26%23xE7%3B%26%23xF5%3Bes%20indesej%26%23xE1%3Bveis%20(veja%20%26%23x93%3BRea%26%23xE7%3B%26%23xF5%3Bes%20Adversas%26%23x94%3B%20em%20INFORMA%26%23xC7%3B%26%23xD5%3BES%20T%26%23xC9%3BCNICAS).%20Informe%20ao%20seu%20m%26%23xE9%3Bdico%20o%20aparecimento%20de%20rea%26%23xE7%3B%26%23xF5%3Bes%20desagrad%26%23xE1%3Bveis.%20%3Cbr%3E%20TODO%20MEDICAMENTO%20DEVE%20SER%20MANTIDO%20FORA%20DO%20ALCANCE%20DAS%20CRIAN%26%23xC7%3BAS.%20%3Cbr%3E%20Ingest%26%23xE3%3Bo%20concomitante%20com%20outras%20subst%26%23xE2%3Bncias%3A%20%3Cbr%3E%20Informe%20ao%20seu%20m%26%23xE9%3Bdico%20sobre%20qualquer%20medicamento%20que%20esteja%20usando%2C%20antes%20do%20in%26%23xED%3Bcio%2C%20ou%20durante%20o%20tratamento%2C%20especialmente%20medicamentos%20para%20press%26%23xE3%3Bo%20alta%2C%20principalmente%20diur%26%23xE9%3Bticos%20poupadores%20de%20pot%26%23xE1%3Bssio%2C%20suplementos%20de%20pot%26%23xE1%3Bssio%20ou%20substitutos%20do%20sal%20que%20contenham%20pot%26%23xE1%3Bssio%2C%20l%26%23xED%3Btio%2C%20antiinflamat%26%23xF3%3Brios%20n%26%23xE3%3Bo-esteroidais%20(AINEs)%2C%20ritonavir%20e%20agentes%20bloqueadores%20de%20RAAS..%20%3Cbr%3E%20Contra-indica%26%23xE7%3B%26%23xF5%3Bes%20e%20precau%26%23xE7%3B%26%23xF5%3Bes%3A%20Este%20medicamento%20%26%23xE9%3B%20contra-indicado%20a%20pacientes%20al%26%23xE9%3Brgicos%20a%20valsartana%20ou%20a%20qualquer%20outro%20componente%20da%20formula%26%23xE7%3B%26%23xE3%3Bo.%20Seu%20uso%20%26%23xE9%3B%20tamb%26%23xE9%3Bm%20contra-indicado%20durante%20a%20gravidez%20e%20a%20amamenta%26%23xE7%3B%26%23xE3%3Bo.%20Informe%20ao%20seu%20m%26%23xE9%3Bdico%20se%20tiver%20doen%26%23xE7%3Ba%20dos%20rins%20ou%20do%20f%26%23xED%3Bgado%20ou%20qualquer%20outra%20doen%26%23xE7%3Ba.%20%3Cbr%3E%20Habilidade%20de%20dirigir%20e%2Fou%20operar%20m%26%23xE1%3Bquinas%3A%20O%20paciente%20deve%20estar%20atento%20sobre%20suas%20rea%26%23xE7%3B%26%23xF5%3Bes%20quando%20dirigir%20ve%26%23xED%3Bculos%20e%2Fou%20operar%20m%26%23xE1%3Bquinas%20ou%20realizar%20outras%20tarefas%20que%20exijam%20aten%26%23xE7%3B%26%23xE3%3Bo%2C%20pois%2C%20como%20muitos%20outros%20medicamentos%20usados%20no%20tratamento%20da%20press%26%23xE3%3Bo%20alta%2C%20DIOVAN%20pode%20afetar%20a%20capacidade%20de%20concentra%26%23xE7%3B%26%23xE3%3Bo.%3Cbr%3E%20N%26%23xC3%3BO%20TOME%20REM%26%23xC9%3BDIO%20SEM%20O%20CONHECIMENTO%20DO%20SEU%20M%26%23xC9%3BDICO.%20PODE%20SER%3Cbr%3E%20PERIGOSO%20PARA%20SUA%20SA%26%23xDA%3BDE.%3Cbr%3E%3C%2Fp%3E%0A%3Ch2%3EData%20da%20bula%3C%2Fh2%3E%0A%3Cp%3E09%2F01%2F2012%3C%2Fp%3E%0A
Ame
Não
ApresentarPrecoDePor
Sim
PBM
Sim
DescontoPBM
11
AdministradoraPBM
SevenPdv
custom_label_0
campanha
EanPBM
7896261012608
MedicamentoControlado
Não
ProgramaPBM
Programa PBM - Industria
MenorPrecoPBM
183.45
LinkLogoProgramaPBM
https://varejo40.blob.core.windows.net/acquirer/027.jpg?sp=rl&st=2021-01-07T18:38:56Z&se=2031-01-08T18:38:00Z&sv=2019-12-12&sr=b&sig=%2BwjVxVwE5F8datPe76G7FhmFrizFR1Vgd9pf5uueZDo%3D
Cashback
Não
Antibiotico
Não
Generico
Não

Tributos e contexto fiscal
Escolha o estado para ver os tributos deste produto:
Preferência salva neste navegador; confirme o destino da operação.

NCM, CEST e tributos são referências fiscais brasileiras e podem não se aplicar em outros países.

Selecione a UF nesta seção para consultar a estimativa IBPT.

IBS/CBS: o cClassTrib acima vem do enquadramento do NCM; percentuais dependem da operação, regime, data e destino.

Medicamento — dados oficiais

Medicamento
DIOVAN AMLO FIX (320 + 10) MG COM REV CT BL AL AL X 28
Princípio ativo
BESILATO DE ANLODIPINO + VALSARTANA
Laboratório
NOVARTIS BIOCIENCIAS S.A
Registro ANVISA
1006810530028
Classe terapêutica
C9D3 - ANTAGONISTAS DA ANGIOTENSINA II ASSOCIADOS A ANTAGONISTAS DO CÁLCIO
Tipo
Novo
Tarja
Tarja Vermelha
PIS/COFINS
Lista positiva (PIS/COFINS monofásico, com crédito presumido)

Fonte: CMED/ANVISA, lista de preços de medicamentos publicada em 09/10/2026. Confirme a tributação com seu contador.

DIOVAN AMLO FIX VALSARTANA 320MG ANLODIPINO 10MG NOVARTIS CAIXA 28 COMPRIMIDOS REVESTIDOS - N/A

Dados estruturados

Veja todos os dados deste produto em JSON.

É exatamente o que a API devolve para este código de barras — pronto para o seu ERP, PIM ou PDV.

GET https://global.si5.com.br/api/produtos/7896261012608


            

                
Para chamar a API de verdade você usa um token pessoal — grátis até 100 consultas por dia.

                

                    Criar conta grátis
                    Documentação
                    Planos
                

            

        

    

    
            
        

        
            

                

                    
Histórico de preços

                    
Como o preço deste produto variou.

                    
Preços de referência coletados em lojas online. Uma nova coleta acontece a cada cerca de 30 dias e sempre que o preço muda.

                    
                


                

                    
Último preçoR$ 189,99

                    
Variação no período—

                    
Menor / maiorR$ 189,99 / R$ 189,99

                    
Coletas1

                


                
                

                    

                        
DataPreçoVariaçãoFonte

                        
                                                            

                                    03/10/2026
                                    R$ 189,99
                                    
                                                                                    primeira coleta
                                                                            
                                    paguemenos.com.br
                                

                                                    
                    

                


                

                    
Valores informativos coletados de lojas online, sem garantia de que estejam atualizados. Não representam preço de venda do SI5 Global.